AptarGroup (ATR) Investor Day 2025 summary

Strategic priorities and value creation

• Focus on profitable growth through innovation, operational efficiency, sustainability, and disciplined capital allocation, with a global reach and ESG leadership integrated across all segments.

• Raised ROIC target by 100 basis points to 12%-14%, reflecting confidence in execution and productivity improvements.

• Dividend increased by nearly 7%, maintaining a payout ratio of 30%-40%, with 32 consecutive years of increases and about 70% of capital reinvested for growth.

• M&A remains a key growth lever, focusing on accretive deals in pharma, beauty science, and sustainability, with disciplined integration.

• Strong balance sheet and capital discipline support long-term investments, flexibility, and shareholder returns.

Segment performance and growth drivers

• Pharma segment leads with proprietary drug delivery systems, robust pipeline, and 7%-11% long-term revenue growth target; injectables, digital health, and regulatory services are key growth areas.

• Beauty segment targets 3-6% core sales growth, improved profitability through innovation, sustainability, and regional expansion, especially in China.

• Closures segment consolidated in 2023, achieving EBITDA margin targets and leveraging regional manufacturing for growth, especially in the U.S., Middle East, Africa, and LATAM.

• All segments benefit from global supply chain, regional expertise, cross-segment technology sharing, and innovation in sustainable packaging.

• Operational efficiency, cost management, and regional expansion are emphasized, particularly in high-growth markets like Asia.

Financial performance and guidance

• Achieved 8% reported sales growth and 49% adjusted EPS growth from 2022-2024, with adjusted EBITDA margin at 21.6%-21.7% and $110M in structural cost savings since 2022.

• Long-term targets: 4%-7% core sales growth, 21%-23% adjusted EBITDA margin, 12%-14% ROIC, and 30%-40% dividend payout ratio.

• Free cash flow conversion now at 10% of sales, with a credible path to 50% of EBITDA over the long term as capital intensity moderates.

• Capital intensity expected in the 7%-9% range, with most investments directed to Pharma; large CapEx projects completed, future investments to be incremental.

• ROIC increased 40% from 2022-2024, supporting the raised target; 30% of capital returned to shareholders, mainly via dividends and buybacks.